ArticleEndocrine2026
Deciphering the immune landscape of parathyroid carcinoma: implications for immunotherapeutic responsiveness.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParathyroid carcinoma is a rare endocrine malignancy with limited therapeutic options. Immune checkpoint blockade targeting the PD-1/PD-L1 axis has transformed the management of several solid tumors; however, its role in parathyroid carcinoma remains largely unexplored. Given that the response to immunotherapy is influenced not only by PD-L1 expression but also by the tumor immune microenvironment (TIME), characterization of the immune landscape in parathyroid carcinoma may provide insights into its potential therapeutic vulnerability.
objectiveTo evaluate PD-L1 expression and comprehensively characterize the tumor immune microenvironment in parathyroid carcinoma, enabling identification of features predictive of immunotherapeutic responsiveness.
methodsUsing immunohistochemistry and multiplex immunofluorescence, this ambispective study investigated parathyroid carcinoma, parathyroid adenoma, and normal parathyroid tissues for PD-L1 expression (clone SP263, Ventana), infiltrating immune cells, namely cytotoxic T lymphocytes (CTLs; CD3⁺CD8⁺), regulatory T cells (Tregs; CD4⁺CD25⁺FOXP3⁺), and monocytic myeloid-derived suppressor cells (MDSCs; CD11b⁺CD14⁺). Immune cell densities were quantified per mm², and the TIME was categorized into four types based on PD-L1 expression and the presence of CTLs: Type I (PD-L1⁺/CTL-rich, adaptive immune resistance), Type II (PD-L1⁻/CTL-poor, immune ignorance), Type III (PD-L1⁺/CTL-poor, intrinsic induction), and Type IV (PD-L1⁻/CTL-rich, immune tolerance).
resultsWhile 30% of adenomas showed patchy PD-L1 positivity (Tumor proportion score, TPS 3-6%), all carcinomas and normal parathyroid tissues were PD-L1-negative (TPS < 1%). Among the immune cells, CTLs and MDSCs were more abundant in the TIME of parathyroid carcinomas than in adenomas and normal tissues. Tregs were rare or absent. Parathyroid carcinomas demonstrated immune-tolerant (Type IV) or immunologically ignorant (Type II) microenvironmental profiles.
conclusionsParathyroid carcinomas predominantly exhibit a PD-L1-independent immune-tolerant microenvironment, rich in CTLs and MDSCs. The results predict a limited benefit from single-agent PD-1/PD-L1 blockade and the need for myeloid-targeting and immune-priming multimodal strategies.
Indexed as
Identifiers
42570161What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.